Surveillance imaging after first-line therapy was not linked with improved survival in patients with mantle cell lymphoma (MCL), according to a retrospective cohort study involving 217 individuals. Participants were from 2 academic institutions and completed first-line therapy for MCL. Investigators looked at surveillance imaging’s impact on survival. Among the results:

• 102 patients relapsed.
• 37% were diagnosed by surveillance imaging.
• Diagnosing relapse via surveillance imaging did not significantly impact overall survival from diagnosis date or relapse date.
• PET/CT had a positive predictive value of 24%, and number needed-to-scan/treat of 51 to detect 1 relapse.
• For CT, these numbers were 49% and 24, respectively.